• Please log in or register to access this feature.
You have full text access to this OnlineOpen article

CD4+CD25+ regulatory T cells in irritable bowel syndrome patients

  1. N. Holmén1,2,
  2. S. Isaksson1,2,
  3. M. Simrén1,
  4. H. Sjövall1,
  5. L. öhman1,2

Article first published online: 13 DEC 2006

DOI: 10.1111/j.1365-2982.2006.00878.x

Issue

Neurogastroenterology & Motility

Neurogastroenterology & Motility

Volume 19, Issue 2, pages 119–125, February 2007

Additional Information

How to Cite

Holmén, N., Isaksson, S., Simrén, M., Sjövall, H. and öhman, L. (2007), CD4+CD25+ regulatory T cells in irritable bowel syndrome patients. Neurogastroenterology & Motility, 19: 119–125. doi: 10.1111/j.1365-2982.2006.00878.x

Author Information

  1. 1

    Department of Internal Medicine, The Sahlgrenska Academy, Göteborg University, Göteborg, Sweden

  2. 2

    Department of Microbiology and Immunology, The Sahlgrenska Academy, Göteborg University, Göteborg, Sweden

*L. Öhman, Department of Microbiology and Immunology, Göteborg University, Box 435, 40530 Göteborg, Sweden. Tel.: +46 31 773 6214; fax: +46 31 773 6205; e-mail: lena.ohman@microbio.gu.se

Publication History

  1. Issue published online: 13 DEC 2006
  2. Article first published online: 13 DEC 2006
  3. Received: 1 February 2006 Accepted for publication: 16 September 2006

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (574K)

References

  • 1
    Agreus L, Svärdsudd K, Nyren O et al. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology 1995; 109: 671–80.
  • 2
    Thompson WG, Longstreth GF, Drossman DA et al. Functional bowel disorders and functional abdominal pain. Gut 1999; 45 (Suppl. 2): II43–7.
  • 3
    Kellow JE, Phillips SF, Miller LJ et al. Dysmotility of the small intestine in irritable bowel syndrome. Gut 1988; 29: 1236–43.
  • 4
    Simrén M, Castedal M, Svedlund J et al. Abnormal propagation pattern of duodenal pressure waves in the irritable bowel syndrome (IBS) [correction of (IBD)]. Dig Dis Sci 2000; 45: 2151–61.
  • 5
    Mertz H, Naliboff B, Munakata J et al. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995; 109: 40–52.
  • 6
    Slater BJ, Plusa SM, Smith AN et al. Rectal hypersensitivity in the irritable bowel syndrome. Int J Colorectal Dis 1997; 12: 29–32.
  • 7
    King TS, Elia M, Hunter JO. Abnormal colonic fermentation in irritable bowel syndrome. Lancet 1998; 352: 1187–9.
  • 8
    Posserud I, Agerforz P, Ekman R et al. Altered visceral perceptual and neuroendocrine response in patients with irritable bowel syndrome during mental stress. Gut 2004; 53: 1102–8.
  • 9
    Simren M, Abrahamsson H, Björnsson ES. An exaggerated sensory component of the gastrocolonic response in patients with irritable bowel syndrome. Gut 2001; 48: 20–7.
  • 10
    Törnblom H, Abrahamsson H, Barbara G et al. Inflammation as a cause of functional bowel disorders. Scand J Gastroenterol 2005; 40: 1140–8.
  • 11
    Törnblom H, Lindberg G, Nyberg B et al. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology 2002; 123: 1972–9.
  • 12
    Chadwick VS, Chen W, Shu D et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002; 122: 1778–83.
  • 13
    Barbara G, De Giorgio R, Stanghellini V et al. A role for inflammation in irritable bowel syndrome? Gut 2002; 51 (Suppl. 1): i41–4.
  • 14
    Spiller RC, Jenkins D, Thornley JP et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000; 47: 804–11.
  • 15
    Öhman L, Isaksson S, Lundgren A et al. A controlled study of colonic immune activity and beta7+ blood T lymphocytes in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2005; 3: 980–6.
  • 16
    Gonsalkorale WM, Perrey C, Pravica V et al. Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component? Gut 2003; 52: 91–3.
  • 17
    Gwee KA, Collins SM, Read NW et al. Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome. Gut 2003; 52: 523–6.
  • 18
    Sakaguchi S, Sakaguchi N, Asano M et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155: 1151–64.
  • 19
    Baecher-Allan C, Brown JA, Freeman GJ et al. CD4+CD25high regulatory cells in human peripheral blood. J Immunol 2001; 167: 1245–53.
  • 20
    Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004; 22: 531–62.
  • 21
    Holmén N, Lundgren A, Lundin S et al. Functional CD4+CD25high regulatory T cells are enriched in the colonic mucosa of patients with active ulcerative colitis and increase with disease activity. Inflamm Bowel Dis 2006; 12: 447–56.
    Direct Link:
  • 22
    Makita S, Kanai T, Oshima S et al. CD4+CD25bright T cells in human intestinal lamina propria as regulatory cells. J Immunol 2004; 173: 3119–30.
  • 23
    Lindley S, Dayan CM, Bishop A et al. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 2005; 54: 92–9.
  • 24
    Viglietta V, Baecher-Allan C, Weiner HL et al. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004; 199: 971–9.
  • 25
    Lundgren A, Strömberg E, Sjöling A et al. Mucosal FOXP3-expressing CD4+ CD25high regulatory T cells in Helicobacter pylori-infected patients. Infect Immun 2005; 73: 523–31.
  • 26
    Read S, Malmström V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 2000; 192: 295–302.
  • 27
    Mottet C, Uhlig HH, Powrie F. Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells. J Immunol 2003; 170: 3939–43.
  • 28
    Denning TL, Kim G, Kronenberg M. Cutting edge: CD4+CD25+ regulatory T cells impaired for intestinal homing can prevent colitis. J Immunol 2005; 174: 7487–91.
  • 29
    Collins S. A case for an immunological basis for irritable bowel syndrome. Gastroenterology 2002; 122: 2078–9.
  • 30
    Bogomoletz WV. Collagenous, microscopic and lymphocytic colitis. An evolving concept. Virchows Arch 1994; 424: 573–9.
  • 31
    Wing K, Suri-Payer E, Rudin A. CD4+CD25+-regulatory T cells from mouse to man. Scand J Immunol 2005; 62: 1–15.
    Direct Link:
  • 32
    Maul J, Loddenkemper C, Mundt P et al. Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology 2005; 128: 1868–78.
  • 33
    Mottonen M, Heikkinen J, Mustonen L et al. CD4+ CD25+ T cells with the phenotypic and functional characteristics of regulatory T cells are enriched in the synovial fluid of patients with rheumatoid arthritis. Clin Exp Immunol 2005; 140: 360–7.
    Direct Link:
  • 34
    Cao D, Van Vollenhoven R, Klareskog L et al. CD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease. Arthritis Res Ther 2004; 6: R335–46.
  • 35
    Tsaknaridis L, Spencer L, Culbertson N et al. Functional assay for human CD4+CD25+ Treg cells reveals an age-dependent loss of suppressive activity. J Neurosci Res 2003; 74: 296–308.
    Direct Link:
  • 36
    Gottenberg JE, Lavie F, Abbed K et al. CD4+CD25high regulatory T cells are not impaired in patients with primary Sjogren's syndrome. J Autoimmun 2005; 24: 235–42.
View Full Article (HTML) Get PDF (574K)